Latest Life Sciences News

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Ryder Capital posted a robust 33.53% pre-tax NTA return for FY26, far outpacing market benchmarks, and announced a fully franked 12 cents per share dividend for FY27, underscoring confidence in its small-cap portfolio.

Lendlease has partnered with The Crown Estate to form the Impact Partnership Joint Venture, unlocking a £24 billion UK development pipeline including up to 30,000 new homes and nearly a million square metres of office and life sciences space.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

ALS Limited (ASX:ALQ) has delivered a landmark FY26 with underlying net profit after tax surging 25.8% to $381.2 million, beating 2027 targets a year early and raising its dividend by 10%. The company continues to invest heavily in automation, digital initiatives, and laboratory expansions while advancing its climate strategy amid a post-year-end cyber incident.

Lendlease is selling its 25.1% stake in the Keyton Retirement Living Trust to Aware Super for $525 million, part of a broader $3.4 billion capital recycling push aimed at debt reduction.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.